Group One Trading’s Damora Therapeutics DMRA Stock Holding History

Group One Trading’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-796	Closed	-$14.3K	–	7660
2023 Q3	$14.3K	Hold	796	–	–	﹤0.01%	6128
2023 Q2	$50.1K	Buy	+796	New	+$43.3K	﹤0.01%	5275

Other funds holding DMRA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Group One Trading's DMRA Position: Q2 2025 in Review

Group One Trading sold out of Damora Therapeutics (DMRA) in Q2 2025, closing a stake of 3 shares — an estimated $9 sold.

Group One Trading first reported a position in DMRA in Q2 2024 and held it in 4 quarters. The position peaked at $37 in Q3 2024. 9 funds tracked by Wall St. Rank hold DMRA as of Q2 2025.

Group One Trading reported no remaining Damora Therapeutics position as of Q2 2025 after selling out during the quarter.
Group One Trading sold 3 Damora Therapeutics shares in Q2 2025, an estimated $9.
Group One Trading first reported a position in Damora Therapeutics in Q2 2024 and held it in 4 quarters.
Group One Trading's Damora Therapeutics position peaked at $37 in Q3 2024.
9 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2025.

Based on Group One Trading's 13F filing for Q2 2025, filed 14 Aug 2025.